A Pharmacokinetics/Dynamics Ib Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy
A Phase Ib Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of F-627 as Prophylaxis Therapy to TAC Chemotherapy in Women With Breast Cancer
Sponsor: EVIVE Biotechnology
Listed as NCT02522234, this PHASE1/PHASE2 trial focuses on Neutropenia and remains completed. Sponsored by EVIVE Biotechnology, it has been updated 10 times since 2014, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Mar 2022 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Mar 2022 [monthly]
Completed PHASE1_PHASE2
-
Dec 2019 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
▶ Show 5 earlier versions
-
Jun 2018 — Dec 2019 [monthly]
Completed PHASE1_PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
Status: Unknown Status → Completed
-
Sep 2017 — Mar 2018 [monthly]
Unknown Status PHASE1_PHASE2
Status: Recruiting → Unknown Status
-
Feb 2017 — Sep 2017 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Feb 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- EVIVE Biotechnology
- Fudan University
- Sun Yat-sen University
For direct contact, visit the study record on ClinicalTrials.gov .